<VariationArchive VariationID="1363699" VariationName="NM_000334.4(SCN4A):c.3263dup (p.Phe1089fs)" VariationType="Duplication" Accession="VCV001363699" Version="4" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-07-15" DateCreated="2022-03-28" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1389519" VariationID="1363699">
      <GeneList>
        <Gene Symbol="GH-LCR" FullName="growth hormone locus control region" GeneID="106128904" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>17q23.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="63917193" stop="63958852" display_start="63917193" display_stop="63958852" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="SCN4A" FullName="sodium voltage-gated channel alpha subunit 4" GeneID="6329" HGNC_ID="HGNC:10591" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>17q23.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="63938554" stop="63972918" display_start="63938554" display_stop="63972918" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="62015913" stop="62050277" display_start="62015913" display_stop="62050277" Strand="-" />
          </Location>
          <OMIM>603967</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000334.4(SCN4A):c.3263dup (p.Phe1089fs)</Name>
      <CanonicalSPDI>NC_000017.11:63947944:CC:CCC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>17q23.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="63947944" stop="63947945" display_start="63947944" display_stop="63947945" variantLength="1" positionVCF="63947944" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="62025304" stop="62025305" display_start="62025304" display_stop="62025305" variantLength="1" positionVCF="62025304" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
      </Location>
      <ProteinChange>F1089fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.62025306dup" Assembly="GRCh37">
            <Expression>NC_000017.10:g.62025306dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.11" sequenceAccession="NC_000017" sequenceVersion="11" change="g.63947946dup" Assembly="GRCh38">
            <Expression>NC_000017.11:g.63947946dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011699.1" sequenceAccession="NG_011699" sequenceVersion="1" change="g.29974dup">
            <Expression>NG_011699.1:g.29974dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_042788.1" sequenceAccession="NG_042788" sequenceVersion="1" change="g.30854dup">
            <Expression>NG_042788.1:g.30854dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000334.4" sequenceAccession="NM_000334" sequenceVersion="4" change="c.3263dup" MANESelect="true">
            <Expression>NM_000334.4:c.3263dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000325.4" sequenceAccession="NP_000325" sequenceVersion="4" change="p.Phe1089fs">
            <Expression>NP_000325.4:p.Phe1089fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2144782598" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000334.4(SCN4A):c.3263dup (p.Phe1089fs) AND Hyperkalemic periodic paralysis" Accession="RCV001937133" Version="5">
        <ClassifiedConditionList TraitSetID="1636">
          <ClassifiedCondition DB="MedGen" ID="C0238357">Hyperkalemic periodic paralysis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-03-18" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-03-18" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-03-28" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">26700687</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1636" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="9510" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Familial hyperkalemic periodic paralysis</ElementValue>
                <XRef ID="304737009" DB="SNOMED CT" />
                <XRef ID="278513006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hyperkalemic periodic paralysis</ElementValue>
                <XRef ID="CN037551" DB="ADAM" />
                <XRef ID="MONDO:0008224" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gamstorp disease</ElementValue>
                <XRef ID="278513006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gamstorp episodic adynamy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Adynamia episodica hereditaria with or without myotonia</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">HYPP</ElementValue>
                <XRef Type="MIM" ID="170500" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="195" />
                <XRef ID="195" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Hyperkalemic periodic paralysis (hyperPP) is characterized by attacks of flaccid limb weakness (which may also include weakness of the muscles of the eyes, throat, breathing muscles, and trunk), hyperkalemia (serum potassium concentration &gt;5 mmol/L) or an increase of serum potassium concentration of at least 1.5 mmol/L during an attack of weakness and/or provoking/worsening of an attack by oral potassium intake, normal serum potassium between attacks, and onset before age 20 years. In approximately half of affected individuals, attacks of flaccid muscle weakness begin in the first decade of life, with 25% reporting their first attack at age ten years or older. Initially infrequent, the attacks then increase in frequency and severity over time until approximately age 50 years, after which the frequency of attacks declines considerably. The major attack trigger is eating potassium-rich foods; other triggers include: cold environment; rest after exercise, stress, or fatigue; alcohol; hunger; and changes in activity level. A spontaneous attack commonly starts in the morning before breakfast, lasts for 15 minutes to one hour, and then passes. Individuals with hyperPP frequently have myotonia (muscle stiffness), especially around the time of an episode of weakness. Paramyotonia (muscle stiffness aggravated by cold and exercise) is present in about 45% of affected individuals. More than 80% of individuals with hyperPP older than age 40 years report permanent muscle weakness and about one third develop a chronic progressive myopathy.</Attribute>
                <XRef ID="NBK1496" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301669</ID>
                <ID Source="BookShelf">NBK1496</ID>
              </Citation>
              <XRef ID="682" DB="Orphanet" />
              <XRef ID="C0238357" DB="MedGen" />
              <XRef ID="MONDO:0008224" DB="MONDO" />
              <XRef Type="MIM" ID="170500" DB="OMIM" />
              <XRef Type="primary" ID="HP:0007215" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4146120" SubmissionDate="2024-02-07" DateLastUpdated="2024-02-28" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="13811008|MedGen:CN074266" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002136492" DateUpdated="2024-02-28" DateCreated="2022-03-28" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-03-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">26700687</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with SCN4A-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Phe1089Leufs*2) in the SCN4A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SCN4A are known to be pathogenic (PMID: 26700687).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SCN4A" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.62025304_62025305insC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN074266" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12506961</SubmissionName>
          <SubmissionName>SUB14200269</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4146120" TraitType="Disease" MappingType="XRef" MappingValue="CN074266" MappingRef="MedGen">
        <MedGen CUI="C0238357" Name="Hyperkalemic periodic paralysis" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

